597 related articles for article (PubMed ID: 24356549)
41. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
42. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
43. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
44. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
[TBL] [Abstract][Full Text] [Related]
45. Pathogenesis and treatment of hepatorenal syndrome.
Arroyo V; Fernandez J; Ginès P
Semin Liver Dis; 2008 Feb; 28(1):81-95. PubMed ID: 18293279
[TBL] [Abstract][Full Text] [Related]
46. [Hepatorenal syndrome].
Pŭrvanov P
Khirurgiia (Sofiia); 2002; 58(2):34-9. PubMed ID: 12515019
[TBL] [Abstract][Full Text] [Related]
47. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
Sharma P; Moore K; Ganger D; Grewal P; Brown RS
Liver Transpl; 2020 Oct; 26(10):1328-1336. PubMed ID: 32574418
[TBL] [Abstract][Full Text] [Related]
48. Vasoconstrictors in hepatorenal syndrome - A critical review.
Mattos ÂZ; Schacher FC; Mattos AA
Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
Salerno F; Cazzaniga M; Merli M; Spinzi G; Saibeni S; Salmi A; Fagiuoli S; Spadaccini A; Trotta E; Laffi G; Koch M; Riggio O; Boccia S; Felder M; Balzani S; Bruno S; Angeli P;
J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
[TBL] [Abstract][Full Text] [Related]
50. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
51. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
Zhang J; Rössle M; Zhou X; Deng J; Liu L; Qi X
Curr Med Res Opin; 2019 May; 35(5):859-868. PubMed ID: 30474439
[TBL] [Abstract][Full Text] [Related]
52. Hepatorenal syndrome: Current concepts related to diagnosis and management.
de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
[TBL] [Abstract][Full Text] [Related]
53. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
[TBL] [Abstract][Full Text] [Related]
54. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
55. Treatment of hepatorenal syndrome.
Kiser TH; Maclaren R; Fish DN
Pharmacotherapy; 2009 Oct; 29(10):1196-211. PubMed ID: 19792993
[TBL] [Abstract][Full Text] [Related]
56. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
[TBL] [Abstract][Full Text] [Related]
57. Hepatorenal syndrome.
Ginès P; Guevara M; Arroyo V; Rodés J
Lancet; 2003 Nov; 362(9398):1819-27. PubMed ID: 14654322
[TBL] [Abstract][Full Text] [Related]
58. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
59. Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
Belcher JM
Med Clin North Am; 2023 Jul; 107(4):781-792. PubMed ID: 37258014
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]